Safety Research Guide

Sedation and somnolence, explained simply with PubMed links

This page translates Sedation and somnolence research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

53research sources

36evidence buckets

PubMedlinked references

What this page is

A plain-English research page about Sedation and somnolence. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 81

Traceable statements carried into the source table.

Human Evidence 30

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 3

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 27

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

Sedation and somnolence has research behind it, but the bucket matters.

This page currently indexes 53 research sources across 36 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 36206805

Human evidence 30 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 36206805

Mechanisms 3 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 36206805

Safety and limits 27 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 36206805

Evidence Buckets

What the Sedation and somnolence research is usually about

Jump to source-backed table

Seizure and neurodevelopmental outcomes

Sedation and somnolence appears in rows studying Seizure and neurodevelopmental outcomes. It currently draws from 10 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36206805

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

Sedation and somnolence appears in rows studying safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37796540

Safety, risk, adverse events, and formulation concerns

Sedation and somnolence appears in rows studying Safety, risk, adverse events, and formulation concerns. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37648266

Sleep

Sedation and somnolence appears in rows studying Sleep. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39980821

drug-interaction mechanisms or safety-relevant outcomes

This bucket groups source-backed rows where Sedation and somnolence is interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. It currently draws from 4 research source(s). PMID 36206805

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Sedation and somnolence appears in rows studying pregnancy, lactation, pediatric, adolescent, or developmental contexts. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37648266

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
Seizure and neurodevelopmental outcomes	Grouped source-backed rows focused on Seizure and neurodevelopmental outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (1), preliminary human (6)	PMID 36206805
safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns	Grouped source-backed rows focused on safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (4)	PMID 37796540
Safety, risk, adverse events, and formulation concerns	Grouped source-backed rows focused on Safety, risk, adverse events, and formulation concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), preliminary human (4)	PMID 37648266
Sleep	Grouped source-backed rows focused on Sleep, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), preliminary human (3)	PMID 39980821
drug-interaction mechanisms or safety-relevant outcomes	Grouped source-backed rows focused on drug-interaction mechanisms or safety-relevant outcomes, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	PMID 36206805
pregnancy, lactation, pediatric, adolescent, or developmental contexts	Grouped source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (3), preliminary human (1)	PMID 37648266
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), preliminary human (1)	PMID 41429020
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), preliminary human (1)	PMID 41429020

Safety Reading Notes

Read safety context beside the research guide.

The Sedation and somnolence source set includes safety-context rows around safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 36206805

Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (4)

PubMed For Dummies Article

Sedation and somnolence Evidence Review: the long-form source walk-through

Quick read

Sedation and somnolence currently has 81 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 36206805
The evidence classes most visible in the row language are preliminary human (39), insufficient (33), mechanistic or pharmacological (8), and preclinical (1). PMID 34468204
The study-design language most visible in the row language is Human clinical study (34), Narrative or expert review (11), Systematic review (11), and other mapped categories (18). PMID 37796540
The repeated topics are Sleep (11), Seizure and neurodevelopmental outcomes (11), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (9), safety, risk, adverse-event, or formulation-specific concerns (8), and other mapped categories (42), which tells the reader where to start opening PubMed and DOI links. PMID 37612115

Start with the research question

Sedation and somnolence is built from 81 source-backed evidence row(s) and 53 research source(s). The current evidence classes read as preliminary human (39), insufficient (33), mechanistic or pharmacological (8), and preclinical (1), and the study-design language most often reads as Human clinical study (34), Narrative or expert review (11), Systematic review (11), and other mapped categories (18). PMID 36206805

The row-level question is not simply whether Sedation and somnolence is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Sleep (11), Seizure and neurodevelopmental outcomes (11), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (9), safety, risk, adverse-event, or formulation-specific concerns (8), and other mapped categories (42). PMID 37796540

Human evidence 30 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 35156171

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 30374683

Mechanistic evidence 3 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 31288397

Limits and uncertainty 60 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 39151115

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 35921510

Where this page has the most source density

The largest bucket surfaced for this page is Seizure and neurodevelopmental outcomes. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns, which gives readers another way to see what the literature repeatedly circles. PMID 36206805

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 37796540

Bucket chapters: what the literature is circling

Seizure and neurodevelopmental outcomes

10 research sources 10 rows (380-422) Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (1), preliminary human (6)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 36206805

Evidence row 380
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis... PMID 36206805
Evidence row 422
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcom... PMID 29540584

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

9 research sources 9 rows (508-516) Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (4)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37796540

Evidence row 508
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human... PMID 37796540
Evidence row 516
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or... PMID 36228902

Safety, risk, adverse events, and formulation concerns

5 research sources 6 rows (217-324) Developed but mixed human research summary: insufficient (2), preliminary human (4)

Evidence row 217
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome... PMID 37648266
Evidence row 324
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical stud... PMID 28538134

Sleep

5 research sources 5 rows (404-414) Developed but mixed human research summary: insufficient (2), preliminary human (3)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 39980821

Evidence row 404
CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 39980821
Evidence row 414
CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 38758300

drug-interaction mechanisms or safety-relevant outcomes

4 research sources 4 rows (22-51) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)

Evidence row 22
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis... PMID 36206805
Evidence row 51
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; ou... PMID 31288397

pregnancy, lactation, pediatric, adolescent, or developmental contexts

4 research sources 4 rows (98-188) Developed but mixed human research summary: insufficient (3), preliminary human (1)

Evidence row 98
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review... PMID 37648266
Evidence row 188
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic revi... PMID 33754312

Pain-related outcomes

3 research sources 3 rows (394-432) Developed but mixed human research summary: insufficient (2), preliminary human (1)

Sedation and somnolence appears in rows studying Pain-related outcomes. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41429020

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41429020

Evidence row 3
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind rand... PMID 37796540
Evidence row 394
CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 41429020
Evidence row 432
CBD studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes). PMID 33118602

Pain-related outcomes

3 research sources 3 rows (473-477) Developed but mixed human research summary: insufficient (2), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41429020

Evidence row 3
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind rand... PMID 37796540
Evidence row 473
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 41429020
Evidence row 477
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 35667066

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (30 row(s)), mechanistic evidence (3 row(s)), and safety/tolerability context (27 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 36206805

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 37796540

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 41142233
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 37648266
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 42207928

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 36206805

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 37796540

Source-reading checklist for Sedation and somnolence

Open the linked PubMed or DOI record. PMID 39980821
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35364618
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 42163693
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 26724101
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 33754312

Source Notes

Sedation and somnolence source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 1
CBN associated with sleep-promoting claims in the pre-2021 evidence base; evidence class: insufficient (study design: narrative review). PMID 34468204
Evidence class: insufficient; Study design: narrative review. Source: Cannabinol and Sleep: Separating Fact from Fiction
Evidence row 2
CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 3
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 14
CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 16
CBN no detected effect on Sleep onset latency; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 17
CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 18
CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue). PMID 37796540
Evidence class: preliminary human; Study design: double-blind randomized placebo-controlled study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 20
CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 37612115
Evidence class: insufficient; Study design: Human clinical study. Source: Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.
Evidence row 22
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: drug-interaction or safety-relevant outcomes). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 24
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes). PMID 35156171
Evidence class: insufficient. Source: A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Evidence row 47
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: drug-interaction or safety-relevant outcomes). PMID 30374683
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Evidence row 51
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 31288397
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.
Evidence row 62
CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 39151115
Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Evidence row 63
CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 35921510
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.
Evidence row 93
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41142233
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacologic treatment of fibromyalgia: an update.
Evidence row 98
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 107
CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes). PMID 42207928
Evidence class: preliminary human. Source: Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis.
Evidence row 108
CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 39980821
Evidence class: preliminary human; Study design: Human clinical study. Source: Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.
Evidence row 110
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 35364618
Evidence class: preclinical; Study design: Human clinical study. Source: Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
Evidence row 161
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42163693
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
Evidence row 175
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 186
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 188
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 33754312
Evidence class: insufficient; Study design: Systematic review. Source: Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Evidence row 196
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 30374683
Evidence class: insufficient; Study design: Human clinical study. Source: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Evidence row 197
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39585547
Evidence class: insufficient; Study design: Narrative or expert review. Source: Update on Cannabidiol in Drug-Resistant Epilepsy.
Evidence row 199
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33667843
Evidence class: insufficient. Source: Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Evidence row 217
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 227
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 42204954
Evidence class: preliminary human; Study design: Human clinical study. Source: A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.
Evidence row 233
THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 39151115
Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Evidence row 234
Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 36791365
Evidence class: insufficient; Study design: Narrative or expert review. Source: Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.
Evidence row 273
THC studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 12648025
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics and pharmacodynamics of cannabinoids.
Evidence row 320
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 321
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 322
THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33536055
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Cannabinoid treatment for autism: a proof-of-concept randomized trial.
Evidence row 323
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 324
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 28538134
Evidence class: preliminary human; Study design: Human clinical study. Source: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Evidence row 354
HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 39323250
Evidence class: preliminary human; Study design: Case report or case series. Source: [Not Available].
Evidence row 365
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 372
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 38904421
Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism and liver toxicity of cannabidiol.
Evidence row 380
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 382
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 33346789
Evidence class: preliminary human; Study design: Human clinical study. Source: Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Evidence row 383
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: seizure-related outcomes). PMID 33754312
Evidence class: insufficient; Study design: Systematic review. Source: Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Evidence row 386
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 36194365
Evidence class: insufficient; Study design: Narrative or expert review. Source: Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Evidence row 388
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: seizure-related outcomes). PMID 40650804
Evidence class: preliminary human. Source: Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.
Evidence row 394
CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 41429020
Evidence class: insufficient; Study design: Systematic review. Source: Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Evidence row 404
CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 39980821
Evidence class: preliminary human; Study design: Human clinical study. Source: Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.
Evidence row 408
CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 35459406
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Effects of Cannabinoids on Sleep.
Evidence row 409
CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525
Evidence class: preliminary human; Study design: Human clinical study. Source: Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Evidence row 413
CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes). PMID 36107800
Evidence class: insufficient; Study design: Systematic review. Source: Cannabis dosing and administration for sleep: a systematic review.
Evidence row 414
CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 38758300
Evidence class: preliminary human; Study design: Human clinical study. Source: Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.
Evidence row 416
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 417
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 29395273
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Evidence row 419
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 420
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 28538134
Evidence class: preliminary human; Study design: Human clinical study. Source: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Evidence row 422
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 29540584
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Evidence row 430
CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 432
CBD studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes). PMID 33118602
Evidence class: preliminary human; Study design: Human clinical study. Source: Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Evidence row 473
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 41429020
Evidence class: insufficient; Study design: Systematic review. Source: Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Evidence row 474
THC studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes). PMID 33118602
Evidence class: preliminary human; Study design: Human clinical study. Source: Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Evidence row 477
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 35667066
Evidence class: insufficient; Study design: Systematic review. Source: Cannabis-Based Products for Chronic Pain : A Systematic Review.
Evidence row 482
THC studied for Nausea and vomiting; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 39151115
Evidence class: preliminary human; Study design: Human clinical study. Source: Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Evidence row 496
THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 9208884
Evidence class: insufficient; Study design: Narrative or expert review. Source: The cancer cachexia syndrome.
Evidence row 497
THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite or metabolic outcomes). PMID 31595793
Evidence class: preliminary human. Source: The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.
Evidence row 500
THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 40631525
Evidence class: preliminary human; Study design: Human clinical study. Source: Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Evidence row 502
THC studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes). PMID 36107800
Evidence class: insufficient; Study design: Systematic review. Source: Cannabis dosing and administration for sleep: a systematic review.
Evidence row 503
THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 32430450
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial.
Evidence row 508
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 37796540
Evidence class: preliminary human; Study design: Human clinical study. Source: A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
Evidence row 509
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 41698831
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
Evidence row 510
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 39980821
Evidence class: preliminary human; Study design: Human clinical study. Source: Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.
Evidence row 511
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 39004335
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.
Evidence row 512
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 37162192
Evidence class: preliminary human; Study design: Human clinical study. Source: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.
Evidence row 513
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 38924151
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes.
Evidence row 514
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 27428345
Evidence class: insufficient; Study design: Narrative or expert review. Source: [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].
Evidence row 515
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 32053725
Evidence class: insufficient. Source: Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research.
Evidence row 516
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 36228902
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes.
Evidence row 629
CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 34569849
Evidence class: preliminary human; Study design: Human clinical study. Source: Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.
Evidence row 636
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42163693
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
Evidence row 700
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 42163693
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
Evidence row 985
THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30194563
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for the Treatment of Epilepsy: an Update.
Evidence row 1145
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 11259648
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.
Evidence row 1175
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 37298321
Evidence class: preliminary human. Source: Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.

Source Trail

Source-backed evidence table and references

53 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

This safety page summarizes source-backed cannabinoid evidence about Sedation and somnolence. It contains 81 evidence row(s); wording should stay descriptive and avoid instructions.

Identity

Canonical name: sedation-somnolence
Type: safety topic
Subtype: Not recorded
Description: Not recorded

Evidence Snapshot

Evidence rows: 81
Sources: 53
Evidence classes: insufficient (33), mechanistic or pharmacological (8), preclinical (1), preliminary human (39)
Draft sections: human evidence (30), mechanistic evidence (3), preclinical evidence (1), safety (27), uncertainty (20)

Key Draft Sections

Human evidence: 30 evidence row(s).
Safety and tolerability: 27 evidence row(s).
Uncertainty and gaps: 20 evidence row(s).
Preclinical evidence: 1 evidence row(s).
Mechanistic evidence: 3 evidence row(s).

Safety Evidence By Compound Or Product

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
Cannabinoids	studied for	Cannabinoids and nausea/vomiting research outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	234
Cannabinoids	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	93
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mechanistic research summary: mechanistic or pharmacological (1)	1	636
CBC	studied for	Skin and inflammatory dermatology	Mechanistic research summary: mechanistic or pharmacological (1)	1	700
CBD	studied for	Anxiety-related outcomes	Early human research summary: preliminary human (2)	2	2 rows (62-63)
CBD	interacts with drug or class	drug-interaction mechanisms or safety-relevant outcomes	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (22-51)
CBD	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (365-372)
CBD	studied for	Pain-related outcomes	Developed but mixed human research summary: insufficient (2), preliminary human (1)	3	3 rows (394-432)
CBD	studied for	pregnancy, lactation, pediatric, adolescent, or developmental contexts	Developed but mixed human research summary: insufficient (3), preliminary human (1)	4	4 rows (98-188)
CBD	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (196-199)
CBD	studied for	safety, risk, adverse-event, or formulation-specific concerns	Developed but mixed human research summary: insufficient (2), preliminary human (4)	5	6 rows (217-324)
CBD	studied for	Seizure and neurodevelopmental outcomes	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (1), preliminary human (6)	10	10 rows (380-422)
CBD	studied for	Sleep	Developed but mixed human research summary: insufficient (2), preliminary human (3)	5	5 rows (404-414)
CBDV	studied for	Seizure and neurodevelopmental outcomes	Preclinical research summary: preclinical (1)	1	110
CBG	studied for	Appetite and metabolic outcomes	Early human research summary: preliminary human (1)	1	629
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mechanistic research summary: mechanistic or pharmacological (1)	1	161
CBN	no detected effect on	Daytime fatigue	Early human research summary: preliminary human (1)	1	18
CBN	decreases	Nighttime awakenings	Early human research summary: preliminary human (1)	1	2
CBN	decreases	Overall sleep disturbance	Early human research summary: preliminary human (1)	1	14
CBN	studied for	safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns	Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (1), preliminary human (4)	9	9 rows (508-516)
CBN	studied for	Sleep	Developed but mixed human research summary: insufficient (1), preliminary human (2)	3	3 rows (20-108)
CBN	no detected effect on	Sleep onset latency	Early human research summary: preliminary human (1)	1	16
CBN	no detected effect on	sleep onset latency, wake after sleep onset, or daytime fatigue	Early human research summary: preliminary human (1)	1	3
CBN	associated with	sleep-promoting claims in the pre-2021 evidence base	Mapped evidence with interpretation limits: insufficient (1)	1	1
CBN	no detected effect on	Wake after sleep onset	Early human research summary: preliminary human (1)	1	17
HHC	studied for	safety, risk, adverse-event, or formulation-specific concerns	Early human research summary: preliminary human (1)	1	354
LEA	studied for	LEA biology, metabolism, physiology, or safety-relevant mechanisms	Early human research summary: preliminary human (1)	1	1175
Noladin ether	studied for	noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	1145
THC	studied for	Appetite and metabolic outcomes	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (496-497)
THC	studied for	Cannabinoids and immune modulation research outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	273
THC	studied for	Cannabinoids and nausea/vomiting research outcomes	Early human research summary: preliminary human (1)	1	233
THC	studied for	Nausea and vomiting	Early human research summary: preliminary human (1)	1	482
THC	studied for	Pain-related outcomes	Developed but mixed human research summary: insufficient (2), preliminary human (1)	3	3 rows (473-477)
THC	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mechanistic research summary: mechanistic or pharmacological (1)	1	322
THC	studied for	Sleep	Developed but mixed human research summary: insufficient (1), preliminary human (2)	3	3 rows (500-503)
THC	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	985

Source-Backed Evidence Table

Evidence Row	Statement	Source
1	CBN associated with sleep-promoting claims in the pre-2021 evidence base; evidence class: insufficient (study design: narrative review).	Cannabinol and Sleep: Separating Fact from FictionPubMed 34468204 DOI 10.1089/can.2021.0006
2	CBN decreases Nighttime awakenings; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: number of awakenings).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
3	CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: sleep onset latency, wake after sleep onset, or daytime fatigue).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
14	CBN decreases Overall sleep disturbance; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: overall sleep disturbance).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
16	CBN no detected effect on Sleep onset latency; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Sleep onset latency).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
17	CBN no detected effect on Wake after sleep onset; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Wake after sleep onset).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
18	CBN no detected effect on Daytime fatigue; evidence class: preliminary human (population or model: Adults 18-55 with poor self-rated sleep quality; study design: double-blind randomized placebo-controlled study; dose: 20 mg CBN; duration: 7 nights; outcome measure: Daytime fatigue).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
20	CBN studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.PubMed 37612115 DOI 10.1136/bmjopen-2022-071148
22	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: drug-interaction or safety-relevant outcomes).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
24	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes).	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.PubMed 35156171 DOI 10.1007/s40263-022-00898-1
47	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: drug-interaction or safety-relevant outcomes).	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.PubMed 30374683 DOI 10.1007/s40263-018-0578-5
51	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes).	Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.PubMed 31288397 DOI 10.3390/jcm8070989
62	CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes).	Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.PubMed 39151115 DOI 10.1200/jco.23.01836
63	CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes).	Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.PubMed 35921510 DOI 10.4088/jcp.21m14130
93	Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Pharmacologic treatment of fibromyalgia: an update.PubMed 41142233 DOI 10.3389/fphar.2025.1651181
98	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
107	CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: sleep-related outcomes).	Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis.PubMed 42207928 DOI 10.1097/jxx.0000000000001289
108	CBN studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.PubMed 39980821 DOI 10.1002/hsr2.70481
110	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes).	Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.PubMed 35364618 DOI 10.1111/epi.17247
161	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
175	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
186	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
188	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
196	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.PubMed 30374683 DOI 10.1007/s40263-018-0578-5
197	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Update on Cannabidiol in Drug-Resistant Epilepsy.PubMed 39585547 DOI 10.1007/s12098-024-05337-1
199	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.PubMed 33667843 DOI 10.1016/j.yebeh.2021.107862
217	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
227	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.PubMed 42204954 DOI 10.1177/10445463261452514
233	THC studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: Cannabinoids and nausea/vomiting research outcomes).	Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.PubMed 39151115 DOI 10.1200/jco.23.01836
234	Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes).	Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.PubMed 36791365 DOI 10.14309/ajg.0000000000002216
273	THC studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes).	Pharmacokinetics and pharmacodynamics of cannabinoids.PubMed 12648025 DOI 10.2165/00003088-200342040-00003
320	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
321	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
322	THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabinoid treatment for autism: a proof-of-concept randomized trial.PubMed 33536055 DOI 10.1186/s13229-021-00420-2
323	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
324	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
354	HHC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (study design: Case report or case series; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	[Not Available].PubMed 39323250 DOI 10.61409/v04240241
365	CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
372	CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Metabolism and liver toxicity of cannabidiol.PubMed 38904421 DOI 10.1080/26896583.2024.2366741
380	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
382	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.PubMed 33346789 DOI 10.1001/jamaneurol.2020.4607
383	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: seizure-related outcomes).	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
386	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.PubMed 36194365 DOI 10.1007/s40263-022-00955-9
388	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: seizure-related outcomes).	Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.PubMed 40650804 DOI 10.1007/s40120-025-00788-w
394	CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes).	Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.PubMed 41429020 DOI 10.7326/annals-25-03152
404	CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.PubMed 39980821 DOI 10.1002/hsr2.70481
408	CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes).	The Effects of Cannabinoids on Sleep.PubMed 35459406 DOI 10.1177/21501319221081277
409	CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.PubMed 40631525 DOI 10.1111/jsr.70124
413	CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes).	Cannabis dosing and administration for sleep: a systematic review.PubMed 36107800 DOI 10.1093/sleep/zsac218
414	CBD studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.PubMed 38758300 DOI 10.1007/s00213-024-06595-9
416	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
417	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.PubMed 29395273 DOI 10.1016/s0140-6736(18
419	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
420	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
422	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.PubMed 29540584 DOI 10.1212/wnl.0000000000005254
430	CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pain-related outcomes).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
432	CBD studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes).	Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.PubMed 33118602 DOI 10.1093/pm/pnaa303
473	THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes).	Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.PubMed 41429020 DOI 10.7326/annals-25-03152
474	THC studied for Pain-related outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: pain-related outcomes).	Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.PubMed 33118602 DOI 10.1093/pm/pnaa303
477	THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: pain-related outcomes).	Cannabis-Based Products for Chronic Pain : A Systematic Review.PubMed 35667066 DOI 10.7326/m21-4520
482	THC studied for Nausea and vomiting; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: nausea, vomiting, or antiemetic outcomes).	Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.PubMed 39151115 DOI 10.1200/jco.23.01836
496	THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes).	The cancer cachexia syndrome.PubMed 9208884
497	THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite or metabolic outcomes).	The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.PubMed 31595793 DOI 10.1177/1534735419881498
500	THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.PubMed 40631525 DOI 10.1111/jsr.70124
502	THC studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: sleep-related outcomes).	Cannabis dosing and administration for sleep: a systematic review.PubMed 36107800 DOI 10.1093/sleep/zsac218
503	THC studied for Sleep; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial.PubMed 32430450 DOI 10.1136/bmjopen-2019-034421
508	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
509	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trialPubMed 41698831 DOI 10.1111/jsr.70284
510	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.PubMed 39980821 DOI 10.1002/hsr2.70481
511	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.PubMed 39004335 DOI 10.1016/j.tox.2024.153885
512	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.PubMed 37162192 DOI 10.1080/27697061.2023.2203221
513	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes.PubMed 38924151 DOI 10.1002/jat.4646
514	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
515	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research.PubMed 32053725 DOI 10.1093/annweh/wxaa013
516	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes.PubMed 36228902 DOI 10.1016/j.fct.2022.113458
629	CBG studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.PubMed 34569849 DOI 10.1089/can.2021.0058
636	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
700	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
985	THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabis for the Treatment of Epilepsy: an Update.PubMed 30194563 DOI 10.1007/s11910-018-0882-y
1145	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.PubMed 11259648 DOI 10.1073/pnas.061029898
1175	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.PubMed 37298321 DOI 10.3390/ijms24119371

Anxiety-related outcomes
Appetite and metabolic outcomes
CBC
CBD
CBDV
CBG
CBN
Cannabinoids
Daytime fatigue
HHC
LEA
Nausea and vomiting
Nighttime awakenings
Noladin ether
Overall sleep disturbance
Pain-related outcomes
Seizure and neurodevelopmental outcomes
Skin and inflammatory dermatology
Sleep
Sleep onset latency

References

Cannabinol and Sleep: Separating Fact from FictionPubMed 34468204 DOI 10.1089/can.2021.0006
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep qualityPubMed 37796540 DOI 10.1037/pha0000682
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.PubMed 37612115 DOI 10.1136/bmjopen-2022-071148
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.PubMed 35156171 DOI 10.1007/s40263-022-00898-1
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.PubMed 30374683 DOI 10.1007/s40263-018-0578-5
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.PubMed 31288397 DOI 10.3390/jcm8070989
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.PubMed 39151115 DOI 10.1200/jco.23.01836
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.PubMed 35921510 DOI 10.4088/jcp.21m14130
Pharmacologic treatment of fibromyalgia: an update.PubMed 41142233 DOI 10.3389/fphar.2025.1651181
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis.PubMed 42207928 DOI 10.1097/jxx.0000000000001289
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial.PubMed 39980821 DOI 10.1002/hsr2.70481
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.PubMed 35364618 DOI 10.1111/epi.17247
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
Update on Cannabidiol in Drug-Resistant Epilepsy.PubMed 39585547 DOI 10.1007/s12098-024-05337-1
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.PubMed 33667843 DOI 10.1016/j.yebeh.2021.107862
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.PubMed 42204954 DOI 10.1177/10445463261452514
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.PubMed 36791365 DOI 10.14309/ajg.0000000000002216
Pharmacokinetics and pharmacodynamics of cannabinoids.PubMed 12648025 DOI 10.2165/00003088-200342040-00003
Cannabinoid treatment for autism: a proof-of-concept randomized trial.PubMed 33536055 DOI 10.1186/s13229-021-00420-2
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
[Not Available].PubMed 39323250 DOI 10.61409/v04240241
Metabolism and liver toxicity of cannabidiol.PubMed 38904421 DOI 10.1080/26896583.2024.2366741
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.PubMed 33346789 DOI 10.1001/jamaneurol.2020.4607
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.PubMed 36194365 DOI 10.1007/s40263-022-00955-9
Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.PubMed 40650804 DOI 10.1007/s40120-025-00788-w
Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.PubMed 41429020 DOI 10.7326/annals-25-03152
The Effects of Cannabinoids on Sleep.PubMed 35459406 DOI 10.1177/21501319221081277
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.PubMed 40631525 DOI 10.1111/jsr.70124
Cannabis dosing and administration for sleep: a systematic review.PubMed 36107800 DOI 10.1093/sleep/zsac218
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.PubMed 38758300 DOI 10.1007/s00213-024-06595-9
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.PubMed 29395273 DOI 10.1016/s0140-6736(18
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.PubMed 29540584 DOI 10.1212/wnl.0000000000005254
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.PubMed 33118602 DOI 10.1093/pm/pnaa303
Cannabis-Based Products for Chronic Pain : A Systematic Review.PubMed 35667066 DOI 10.7326/m21-4520
The cancer cachexia syndrome.PubMed 9208884
The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.PubMed 31595793 DOI 10.1177/1534735419881498
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial.PubMed 32430450 DOI 10.1136/bmjopen-2019-034421
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trialPubMed 41698831 DOI 10.1111/jsr.70284
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.PubMed 39004335 DOI 10.1016/j.tox.2024.153885
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.PubMed 37162192 DOI 10.1080/27697061.2023.2203221
Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes.PubMed 38924151 DOI 10.1002/jat.4646
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research.PubMed 32053725 DOI 10.1093/annweh/wxaa013
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes.PubMed 36228902 DOI 10.1016/j.fct.2022.113458
Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.PubMed 34569849 DOI 10.1089/can.2021.0058
Cannabis for the Treatment of Epilepsy: an Update.PubMed 30194563 DOI 10.1007/s11910-018-0882-y
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.PubMed 11259648 DOI 10.1073/pnas.061029898
Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.PubMed 37298321 DOI 10.3390/ijms24119371

Sedation and somnolence has research behind it, but the bucket matters.

What the Sedation and somnolence research is usually about

Seizure and neurodevelopmental outcomes

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

Safety, risk, adverse events, and formulation concerns

Sleep

drug-interaction mechanisms or safety-relevant outcomes

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

Sedation and somnolence Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

Seizure and neurodevelopmental outcomes

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

Safety, risk, adverse events, and formulation concerns

Sleep

drug-interaction mechanisms or safety-relevant outcomes

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Pain-related outcomes

Pain-related outcomes

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for Sedation and somnolence

Sedation and somnolence source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Safety Evidence By Compound Or Product

Source-Backed Evidence Table

Related Pages

References